Chlorpyrifos has undergone dramatic changes in its market trajectory, from a blockbuster proprietary molecule to a globally traded generic active ingredient. AgriBusiness Global spoke with Ram ...

Highmark recently shared how it increased generic and biosimilar access to members, focusing on drugs for multiple sclerosis, cancer and autoimmune conditions. The insurer has been working with ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...

The fun part about a programming language like C is that although the language doesn’t directly support many features including object-oriented programming and generics, there’s nothing that’s keeping ...

Teva Pharmaceutical Industries Limited has successfully shifted its strategy, leveraging its generics business to fund growth in specialty medicines, driving a turnaround in performance. TEVA's "Pivot ...

Pacira BioSciences faces significant risk as generic challenges threaten Exparel, its flagship product responsible for 78% of 2024 revenue. PCRX's complex formulation, robust patent estate, and ...

CEO Narasimhan says no tariff impact on guidance Top-selling heart drug Entresto sees growth stall Older drugs hit by 'generic erosion' in US market Newer drugs help offset some of the slowdown ...

Dr. Reddy's Laboratories Limited RDY reported second-quarter fiscal 2026 earnings of 19 cents per American Depositary Share (ADS), which beat the Zacks Consensus Estimate of 18 cents. The company ...

Jamie Dimon is right to be alarmed about our national-security vulnerabilities, especially an overreliance on China and India for generic prescription drugs (“Investments for National Security,” op-ed ...